Group 1 (fluticasone) n=27 | Group 2 (placebo) n=26 | Odds ratio (95% CI) | p Value2-150 | |
---|---|---|---|---|
Respiratory status | ||||
Extubation within 7 days | 13 (48.1) | 8 (30.8) | 2.09 (0.59, 7.53) | 0.311 |
Extubation within 14 days | 17 (63.0) | 8 (30.8) | 3.83 (1.06, 14.24) | 0.038 |
Oxygen dependency/death at 28 d | 16 (59.3) | 17 (65.4) | 0.77 (0.22, 2.70) | 0.860 |
Oxygen dependency/death at 36 post conceptional weeks | 6 (22.2) | 12 (46.2) | 0.33 (0.08, 1.27) | 0.121 |
Mortality | 5 (18.5) | 9 (34.6) | 0.43 (0.10, 1.77) | 0.309 |
Systemic steroid required after day 14 | 5 (18.5) | 8 (30.8) | 0.51 (0.11, 2.17) | 0.473 |
Complications | ||||
Hyperglycaemia | ||||
>7 mmol/l | 12 (44.4) | 14 (53.8) | 0.69 (0.20, 2.32) | 0.682 |
>10 mmol/l | 5 (18.5) | 6 (23.1) | 0.76 (0.16, 3.53) | 0.278 |
Hypertension | 5 (18.5) | 4 (15.4) | 1.25 (0.23, 7.16) | 1.000 |
Pneumothorax | 1 (3.7) | 2 (7.7) | 0.46 (0.01, 9.53) | 0.610 |
PDA requiring treatment | 17 (63.0) | 20 (76.9) | 0.51 (0.13, 1.97) | 0.142 |
Indomethacin | 13 (48.1) | 19 (73.1) | 0.34 (0.09, 1.24) | 0.116 |
Surgical ligation | 4 (14.8) | 1 (3.8) | 4.35 (0.38, 222.5) | 0.351 |
Necrotising enterocolitis | 7 (25.9) | 8 (30.8) | 0.79 (0.20, 3.05) | 0.931 |
Periventricular haemorrhage | 9 (33.3) | 6 (23.1) | 1.67 (0.43, 6.67) | 0.601 |
Grade III/IV | 3 (11.1) | 3 (11.5) | 0.96 (0.12, 7.92) | 1.000 |
Grade I/II | 6 (22.2) | 3 (11.5) | 2.19 (0.40, 15.04) | 0.467 |
Periventricular leucomalacia | 3 (11.1) | 1 (3.8) | 3.13 (0.23, 170.49) | 0.610 |
Retinopathy of prematurity | 6 (22.2) | 4 (15.4) | 1.57 (0.32, 8.63) | 0.728 |
Stage I | 4 (14.8) | 2 (7.7) | 2.09 (0.27, 24.84) | 0.669 |
Stage II | 2 (7.4) | 2 (7.7) | 0.96 (0.06, 14.24) | 1.000 |
Culture proved sepsis | ||||
First 14 days | 1 (3.7) | 0 (0.0) | Undefined | 1.000 |
Before hospital discharge | 5 (18.5) | 7 (26.9) | 0.62 (0.13, 2.72) | 0.687 |
Pathogens isolated from tracheal aspirate | 11 (40.7) | 9 (34.6) | 0.773 |
↵2-150 χ2 test.